Post-ASH 2015 CML - MPN
|
|
- Randolph Osborne
- 6 years ago
- Views:
Transcription
1 Post-ASH 2015 CML - MPN Fleur Samantha Benghiat, MD, PhD Hôpital Erasme, Brussels
2 1. CML
3 CML 1st line ttt Prognosis Imatinib Nilotinib Response Discontinuation Dasatinib
4 Low RISK PROFILE High 1ST LINE TREATMENT ACCORDING TO RISK PROFILE AND THERAPEUTIC GOAL NILO / DASA NILO / DASA NILO / DASA IMA IMA NILO / DASA IMA IMA NILO / DASA Low TREATMENT FREE REMISSION PRIORITY High Hughes T. White D. ASH 2013
5 CML Prognosis ELTS Score 1st line ttt Response Discontinuation
6 PROGNOSIS OF CHRONIC PHASE - CML EUTOS Long Term Survival Score (ELTS) Pfirrmann M. et al. (Abstract #0595) Sokal Euro/Hasford EUTOS EUTOS Long Term Survival Risk groups (1984) (1998) (2011) ELTS (2015) 1 Chemo IFN-a Imatinib Imatinib CCR 18 mo 8-year probability of CML-related death Age x x 0,0025x(age/10)³ LOW Spleen size x x x + 0,0615 spleen size 2% Blasts % x x + 0,1052 PB blasts INTERMEDIATE Platelet count x + 0,4104x(plt/1000) -0,5 6% Basophils % x x HIGH Eosinophils % x 11% Better id of High risk patients than Sokal Low = Intermediate Low Intermediate Online calculators 1. Pfirrmann M et al. Prognosis of long-term survival considering disease specific death in patients with CML. Leukemia Advance online publication, 3 November 2015; doi: /leu
7 Cumulative incidence probabilities of dying because of CML SOKAL HASFORD N= 2205 patients ELN/EUTOS registry Prospectively enrolled ( ) Imatinib-based ttt Ima 400, 600 or 800 mg Ima + IFNa Ima + Ara-C ELTS Pfirrmann M et al. Prognosis of long-term survival considering disease specific death in patients with CML. Leukemia Advance online publication, 3 November 2015; doi: /leu
8 CML Prognosis ELTS 1st line ttt Ima-Nilo-Dasa Response *Dose optimization Discontinuation *IFN-a
9 How to achieve better response with Imatinib? OPTIM Imatinib trial Rousselot P. et al. Abstract #0133 Personalized imatinib doses by drug monitoring MMR 64%! N=43 N=43 N=133 N=47 Courtesy of P. Rousselot
10 E s tim a te d M M R ra te (% ) OPTIM results by 12 months MMR by 12 months (post randomization) Improved MMR in a magnitude similar to 2 nd gen TKI % 5 0 % p = A d a p te d N o n a d a p te d D a y s s in c e ra n d o m is a tio n to T D M Reason for discontinuation Adapted arm (C1) Non adapted arm (C2) Consent withdrawal 1 1 Adverse event 2 2 Lack of response 1 3 TOTAL % (N) 9% (4) 14% (6) Courtesy of P. Rousselot
11 HOW TO ACHIEVE BETTER RESPONSE? PEG-IFN + Imatinib [SPIRIT, Preudhomme et al. NEJM 2010] High rate of MMR + Nilotinib [NILOPEG, Nicolini FE et al. Lancet Hematology 2015] High rate of deep MR + Dasatinib Roy L. et al. (Abstract #0134) Henrik HH. et al. (Abstract #0477) High early MMR and deep MR 30%) Toxicity profile not negligible but manageable
12 CML Prognosis ETLT 1st line ttt Ima/Nilo/Dasa Response Discontinuation
13 Etienne G. et al. (Abstract #0345 ) (= MR 5.0) 65 months follow up Courtesy of Pr Etienne G.
14 - Sokal = Strong factor associated with recurrence - 2 nd deep MR after TKI resumption No molecular recurrence after 24 months Very rare molecular recurrences after 6 months CONCLUSIONS: Imatinib discontinuation is safe provided that: - A deep sustained molecular response have been achieved before discontinuation - A close molecular monitoring is available after treatment discontinuation Courtesy of Pr Etienne G.
15 TKI WITHDRAWAL SYNDROME (WS) Berger M. et al. (Abstract #0137) Musculoskeletal pain after stopping TKI Study Prevalence Onset TKI Location Duration Euroski and STIM-2 (n= 428) 24% 21 days Imatinib and nilotinib (n=2) Shoulders Spine A few weeks to several months Risk factors R/ Time on TKI Previous history of osteo-articular symptoms NSAIDs, corticosteroids or local infiltration Restart TKIs: WS disappeared in 50% after a median of 3 weeks
16 2. Myelofibrosis
17 DIAGNOSIS PROPOSED REVISED CRITERIA WHO 2015 WHO 2008 WHO 2015 revised MF Diagnosis PMF Barbui T et al. Blood Cancer J. 2015;5:e337 Courtesy of Pr C. Harrison
18 MF: ESMO GUIDELINES FOR DIAGNOSIS AND TREATMENT MF Prognosis Vannucchi AM, et al. Ann Oncol. 2015; 26:v85-v99 Courtesy of Pr Vannucchi
19 MIPSS MOLECULAR - IPSS IPSS 2009 DIPSS 2010 DIPSS MIPSS 2014 Weighted Value Age 1,5 Symptoms 0,5 WBC Hb < 10 g/dl 0,5 PB Blasts > 1% Platelet count 1 RBC transfusion Karyotype Mutational status Triple neg 1,5 JAK2/MPL 0,5 ASXL1 0,5 SRSF2 0,5 Risk Score OS, y Low 0-0,5 26,4 Int-1 1-1,5 9,7 Int-2 2-3,5 6,4 High 4 1,9 Utility of MIPSS: Potential allosct candidates in current Int-1 and Int-2 IPSS risk category Vannucchi AM, et al. Blood (Annual Meeting Abstract). 2014,124, abstract 405
20 MF: ESMO GUIDELINES FOR DIAGNOSIS AND TREATMENT MF IPSS DIPSS (+) MIPSS Low / Int-1 Symptomatic No Yes *Observation *Conventional treatment (Spleen HU ) Int-2 / High Vannucchi AM, et al. Ann Oncol. 2015; 26:v85-v99 Courtesy of Pr Vannucchi
21 MF: ESMO GUIDELINES FOR DIAGNOSIS AND TREATMENT MF IPSS DIPSS (+) MIPSS Low / Int-1 Symptomatic No Yes *Observation *Conventional treatment (Spleen HU ) Int-2 / High AlloSCT eligible? Yes AlloSCT *Conventional *RIC Vannucchi AM, et al. Ann Oncol. 2015; 26:v85-v99 Courtesy of Pr Vannucchi
22 ALLO SCT IN PMF Consensus process by an EBMT/ELN international working group 1. IPSS or DIPSS int-2 or high-risk, age <70y Potential candidates for SCT 2. Int-1-risk and age <60y Potential candidates for SCT if Refractory transfusion-dependent anemia Refractory symptomatic splenomegaly Peripheral blood blast >2% OR adverse cytogenetics (as in DIPSS+) 3. Int-1-risk triple negative and/or ASXL1+ Considered for allo-sct 4. Low-risk No SCT Evaluation for SCT when progression Kröger N, et al. Leukemia epub ahead of print. Courtesy of Pr Vannucchi
23 MF: ESMO GUIDELINES FOR DIAGNOSIS AND TREATMENT No *Observation Low / Int-1 Symptomatic Yes *Conventional treatment (Spleen HU ) MF IPSS DIPSS (+) MIPSS Platelets > /mm³ Splenomegaly Int-2 / High AlloSCT eligible? No *Ruxolitinib *Drugs for anemia *Clinical trials Yes AlloSCT *Conventional *RIC Vannucchi AM, et al. Ann Oncol. 2015; 26:v85-v99 Courtesy of Pr Vannucchi
24 RUXOLITINIB COMFORT 2 5 YEARS FINAL RESULTS Harrison C, et al. #059 Randomized, open-label, multicenter phase 3 study MF with 2 IPSS N=219 Randomize 2:1 Treatment until progressive splenomegaly unless discontinued earlier for splenectomy, toxicity or death BAT: Crossover allowed for patients with progressive splenomegaly Ruxolitinib 15 or 20 mg BID N= 146 Best Available Therapy (BAT) N= 73 Crossover to Ruxolitinib N= 45 Primary results and 3-year follow-up: - Primary endpoint reached: 35% reduction spleen volume at week 48 : Ruxolitinib 28% vs BAT 0% (p<.0001) - Sustained spleen volume reduction at 3-years
25 RESULTS Spleen response Median duration: 3,2 y The K-M estimated probability of maintaining response Ruxolitinib a n = 78 BAT a n = 1 5 years, 0.48 Events Censored 34 (43.6%) 44 (56.4%) 0 1 (100%) JAK2 V617F allele Burden The majority had a reduction over the course of ttt (1/3 with >20% ) BM fibrosis Improved or stabilized in 48% of patients Safety issues VZV Hb levels during the 12 first weeks then and remained > 10g/dl Thrombocytopenia mainly grade 1-2; 19% grade 3-4 at any time
26 Probability HR, hazard ratio; ITT, intent-to-treat; RPSFT, Rank-Preserving Structural Failure Time. OVERAL SURVIVAL Median Overall Survival Ruxolitinib (ITT) = not reached BAT (ITT) = 4.1 years BAT (RPSFT) = 2.7 years Ruxolitinib BAT (ITT) BAT (RPSFT) Median OS was not yet reached in the RUX arm (ie, > 5 years) 33% reduction in risk of death with RUX vs BAT ITT: HR, 0.67 (95% CI, ); P=.06 confounding effect of cross-over RPSFT (OS correcting for cross-over) n = Time, years HR, 0.44 (95% IC, ) in favor of ruxolitinib vs BAT
27 MF: ESMO GUIDELINES FOR DIAGNOSIS AND TREATMENT No *Observation Low / Int-1 Symptomatic Yes *Conventional treatment (Spleen HU ) MF IPSS DIPSS (+) MIPSS Platelets < /mm³? Int-2 / High AlloSCT eligible? No *Ruxolitinib *Drugs for anemia *Clinical trials Yes AlloSCT *Conventional *RIC Vannucchi AM, et al. Ann Oncol. 2015; 26:v85-v99 Courtesy of Pr Vannucchi
28 Vannucchi MA, et al. #2817 Safely administred Plt x10 9 /L : starting dose of up to 15mg BID Plt x10 9 /L : starting dose of up to 10mg BID No new or unexpected AEs Spleen reduction across all groups Consistent with those observed in patients with higher Plt counts Study still ongoing But revised: Starting dose : 10mg BID for Plt x10 9 /L
29 MF: ESMO GUIDELINES FOR DIAGNOSIS AND TREATMENT No *Observation Low / Int-1 Symptomatic Yes *Conventional treatment (Spleen HU ) MF IPSS DIPSS (+) MIPSS Platelets < /mm³? Int-2 / High AlloSCT eligible? No *Ruxolitinib *Drugs for anemia *Clinical trials Yes AlloSCT *Conventional *RIC Vannucchi AM, et al. Ann Oncol. 2015; 26:v85-v99 Courtesy of Pr Vannucchi
30 FDA New drug Application JAK2 INHIBITORS TESTED IN CLINICAL TRIALS Agent JAK family target Non JAK target Hem toxicity Non-heme toxicity Hem Response APPROVED Ruxolitinib JAK1/2 Plt Hb None III Trial phase Momelotinib JAK1/2 JNK1 CDk2 Plt Neuro Anemia III vs Ruxo Pacritinib JAK2 FLT3 Hb GI None III Phase III PERSIST-1 TRIAL (Vannucchi MA, et al. #058) MF Int-1, Int-2, High risk Palpable spleen 5cm No exclusion for baseline Plt and Hb levels No prior ttt with JAK2 inhibitors R (2:1) Pacritinib 400 mg QD (N=220) BAT excluding Ruxolitinib (N=107) Endpoints - Primary : Spleen volume reduction 35% by week 24 Reached : 19.1% vs 4.7% (p=.0003) - Secondary: Total Symptom Score (TSS) reduction 50% by week 24 Reached Outcome across subgroups (age, Hb, plt, ECOG, JAK2 mutation, RBC transf )
31 Changes in PLT levels, Hb and RBC transfusion dependence over time Achievement of SVR >35% and TSS >50% irrespective of baseline characteristics, including baseline Plt count
32 MF: ESMO GUIDELINES FOR DIAGNOSIS AND TREATMENT Low / Int-1 Symptomatic No Yes *Observation *Conventional treatment (HU ) MF IPSS DIPSS (+) MIPSS Infections? Int-2 / High AlloSCT eligible? No *Ruxolitinib *Drugs for anemia *Clinical trials Yes AlloSCT *Conventional *RIC Vannucchi AM, et al. Ann Oncol. 2015; 26:v85-v99 Courtesy of Pr Vannucchi
33 RISK FACTORS FOR INFECTIONS IN MF Polverelli N. et al. (Abstract #1606) Retrospective, 507 MF patients Infection in 22% MF patients grade 3-4: 45% Bacterial (pneumonia) 89% Increased risk of infection Baseline IPSS int-2 and high Splenomegaly > 10cm Ruxolitinib Positive prognostic factor Spleen reduction > 50% Negative prognostic factor Age >65 Corticosteroids
34 3. Essential Thrombocytemia Don t worry, only 30 slides to go
35 DIAGNOSIS PROPOSED REVISED CRITERIA WHO 2015 WHO criteria 2008 A1 Platelets > 450 x 10 9 /L A2 A3 A4 ET BM biopsy: proliferation mainly of the MK lineage with increased numbers of enlarged mature MKs. No significant increase of neutrophil granulopoïesis or erythropoïesis. Not meeting WHO criteria for BCR-ABL CML, PV, PMF, MDS or other myeloid neoplasm V617F-JAK2 or other clonal marker Or in the absence, no evidence for reactive thrombocytosis A1+A2+A3+A4 Barbui T et al. Blood Cancer J. 2015;5:e337 Proposed WHO criteria 2015 A1 Platelets > 450 x 10 9 /L A2 A3 A4 B ET BM biopsy: proliferation mainly of the MK lineage with increased numbers of enlarged mature MKs. No significant increase of neutrophil granulopoïesis or erythropoïesis, & very rarely minor increase in reticulin fibers. Not meeting WHO criteria for BCR-ABL CML, PV, PMF, MDS or other myeloid neoplasm Presence of JAK2, CALR or MPL mutation Presence of a clonal marker Or absence of evidence for reactive thrombocytosis A1+A2+A3+A4 Or A1+A2+A3+B Courtesy of Pr C. Harrison
36 THROMBOSIS-Free SURVIVAL Practice-relevant revision of ipset-thrombosis based on 1019 patients with WHO-defined ET Barbui T. et al. (Abstract #4055) Low risk Age 60 and no history of thrombosis No add RF CV RF + JAK2 + CV + JAK2 + High risk Age > 60 OR history of thrombosis No add RF CV RF + JAK2 + CV + JAK2 + CVRF- AAS 80/160 CVRF+ AAS 160 Very Low = JAK2 neg CVRF- FU CVRF+ AAS 80 Low = JAK2 + Cytoreduction Intermediate = Age > 60 and JAK2 neg Cytoreduction or AAS 160 High = Thrombosis history OR Age > 60 and JAK2 +! To be confirmed by prospective controlled studies
37 4. Polycythemia Vera
38 DIAGNOSIS PROPOSED REVISED CRITERIA WHO 2015 WHO criteria 2008 Proposed WHO criteria 2015 A1 Hb > 18.5 g/dl, 16.5 OR HCT OR Red Cell Mass (RCM) A1 Hb > 16.5 g/dl, 16.0 OR HCT >0.49 or >0.48 OR RCM A2 B1 JAK2 mutation BM with age-adjusted hypercellularity and panmyelosis A2 A3 BM with age-adjusted hypercellularity, panmyelosis with pleiomorphic mature MK JAK2 mutation B2 EPO B3 Endogenous erythroid colony formation B EPO PV A1+A2 and one B OR A1 and two B PV A1 + A2 + A3 OR A1 + A2 and the B Barbui T et al. Blood Cancer J. 2015;5:e337
39 RESPONSE: RUXOLITINIB IN 2 ND LINE PV + SPLENOMEGALY Results after week 32 Kiladjan JJ. Et al. (Abstract #2804)
40 THANK YOU!
How I treat high risk myeloproliferative neoplasms. Francesco Passamonti Università dell Insubria Varese - Italy
How I treat high risk myeloproliferative neoplasms Francesco Passamonti Università dell Insubria Varese - Italy How I treat high risk MF MF Treatment ELN 2018 Guidelines Anemia (Hb < 10 g/dl) Splenomegaly
More informationClassical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis. Francesco Passamonti Università degli Studi dell Insubria, Varese
Classical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis Francesco Passamonti Università degli Studi dell Insubria, Varese DIPSS during f-up IPSS at diagnosis Diagnose MF and genotype
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationMALATTIE MIELOPROLIFERATIVE CRONICHE
MALATTIE MIELOPROLIFERATIVE CRONICHE Dott. Roberto Latagliata Policlinico Umberto I Università Sapienza, Roma Highlights from EHA 2017: some points to address today WHO 2016 MPN classification: hot topics
More informationUpdate in Myeloproliferative Neoplasms
Update in Myeloproliferative Neoplasms 2018 UPDATE IN HEMATOLOGIC MALIGNANCIES January 26, 2018 Daria Babushok, MD PhD Learning Objectives Philadelphia-chromosome negative MPNs 1. To review key changes
More informationMayo Clinic Treatment Strategy in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis 2013 Update
Mayo Clinic Treatment Strategy in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis 2013 Update Ayalew Tefferi Mayo Clinic, Rochester, MN 0 20 40 60 80 100 Percent Survival in 337 Mayo Clinic
More informationMPNs: JAK2 inhibitors & beyond. Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt
MPNs: JAK2 inhibitors & beyond Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt Myeloproliferative Neoplasms (MPNs) AGENDA: 1. Molecular biology 2. New WHO diagnostic criteria. 3. Risk stratification
More informationHow I Treat Myelofibrosis. Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom
How I Treat Myelofibrosis Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom Primary Myelofibrosis Archiv Fur Pathol. 1879;78:475-96. 2 cases of leukemia with peculiar blood and marrow findings
More informationPolycytemia Vera, Essential Thrombocythemia and Myelofibrosis: prognosis and treatment
Polycytemia Vera, Essential Thrombocythemia and Myelofibrosis: prognosis and treatment BHS Training course 2013-2015 Timothy Devos POLYCYTEMIA VERA PV: clinical manifestations thrombosis (art > ven) facial
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationManaging ET in Tiziano Barbui MD
Managing ET in 2019 Tiziano Barbui MD (tbarbui@asst-pg23.it) Hematology and Foundation for Clinical Research, Hospital Papa Giovanni XXIII Bergamo, Italy Managing ET in 2019 Establish diagnosis Risk Stratification
More informationShould Intermediate-I risk PMF be transplanted immediately or later? Position: Later
Should Intermediate-I risk PMF be transplanted immediately or later? Position: Later Vikas Gupta, MD, FRCP, FRCPath Associate Professor Department of Medicine Leukemia/BMT Programs Princess Margaret Cancer
More informationDisclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms
Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationPractical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology
Practical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology Angela Fleischman MD PhD UC Irvine March 9, 2019 Disclosures: Angela Fleischman
More informationIntro alla patologia. Giovanni Barosi. Fondazione IRCCS Policlinico San Matteo Pavia
Settima Giornata Fiorentina dedicata ai pazienti con malattie mieloproliferative croniche Sabato 13 Maggio 2017 CRIMM Centro di Ricerca e Innovazione per le Malattie Mieloproliferative AOU Careggi Intro
More informationLeukemia and subsequent solid tumors among patients with myeloproliferative neoplasms
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms Tiziano Barbui (tbarbui@asst-pg23.it Hematology and Research Foundation,Ospedale Papa Giovanni XXIII, Bergamo Italy
More informationRESPONSE (NCT )
Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results Abstract #709 Mesa R, Verstovsek S, Kiladjian
More informationEvolving Management of Myelofibrosis
Evolving Management of Myelofibrosis Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Why do we prognosticate?
More informationMPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs
MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs Hans Michael Kvasnicka University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Disclosure of
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationMielofibrosi: inquadramento dei fattori prognostici
Mielofibrosi: inquadramento dei fattori prognostici Francesco Passamon, Division of Hematology University Hospital, Fondazione Macchi Varese, Italy Reduced survival in PMF and causes of death Median OS
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationHow to monitor MPN patients
How to monitor MPN patients MPN carries significant burden and risk Transformation to MF or AML 1 Neurological complications 2 MPN-associated general symptoms (eg, pruritus, fatigue) 3 Microvascular symptoms
More informationHSCT for Myeloproliferative Disorders. Jane Apperley
HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationMyeloproliferative Neoplasms and Myelofibrosis: Evolving Management
Myeloproliferative Neoplasms and Myelofibrosis: Evolving Management Ruben A. Mesa, MD Mayo Clinic Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Evolving Management of MPNs NCCN MPN
More informationWelcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More informationASBMT MDS/MPN Update Sunil Abhyankar, MD
ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine
More informationNovità terapeu-che nelle mala3e mieloprolifera-ve croniche Ph nega-ve. Francesco Passamon- Università dell Insubria Varese - Italy
Novità terapeu-che nelle mala3e mieloprolifera-ve croniche Ph nega-ve Francesco Passamon- Università dell Insubria Varese - Italy ESMO Guidelines for PV Vannucchi et al, Ann Oncol. 2015 Sep;26 Suppl 5:v85-99
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationCLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98
PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationShould Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!
Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Lindsay Anne Magura Rein, MD Division of Hematologic Malignancies and Cellular Therapy/BMT A Little Bit of History.. 1665 Advanced
More informationLondon Cancer. Myelofibrosis guidelines. August Review August Version v1.0. Page 1 of 12
London Cancer Myelofibrosis guidelines August 2013 Review August 2013 Version v1.0 Page 1 of 12 CONTENTS 1. DIAGNOSIS... 3 1a. BCSH (2012)... 3 1b. WHO (2009) diagnostic criteria for PMF:... 4 2. MOLECULAR
More informationPolycthemia Vera (Rubra)
Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Increased red cells Clonal Myeloid lineages also increased 2-13 cases per million Mean age: 60 years Sites of Involvement Bone marrow Peripheral blood
More informationEvolving Guidelines of MPNs Where do new options fit in your treatment plan?
Evolving Guidelines of MPNs Where do new options fit in your treatment plan? 34 th Chemotherapy Foundation Symposia Innovative Cancer Therapy for Tomorrow Ruben A. Mesa, MD, FACP Professor and Chair, Division
More informationLatest updates in Myeloproliferative Neoplasms. Elizabeth Hexner, MD, MSTR
Latest updates in Myeloproliferative Neoplasms Elizabeth Hexner, MD, MSTR Disclosures Nothing to disclose Agenda/Goals Treatment goals in PV Indications for cytoreduction in patients polycythemia vera
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationStifel Nicolaus 2013 Healthcare Conference. John Scarlett, M.D. Chief Executive Officer September 11, 2013
Stifel Nicolaus 2013 Healthcare Conference John Scarlett, M.D. Chief Executive Officer September 11, 2013 1 forward-looking statements Except for the historical information contained herein, this presentation
More informationMyeloproliferative Neoplasms and Treatment Overview
Myeloproliferative Neoplasms and Treatment Overview George Nesr Clinical Research Fellow in Haematology Haematology Department Imperial College Healthcare NHS Trust Overview Historical Background Pathogenesis
More informationChi sono i candidati agli inibitori di JAK2
Chi sono i candidati agli inibitori di JAK2 Francesco Passamon, Hematology, University Hospital Varese, Italy Ruxoli8nib (US approved in MF; EAP study and compassionate use in Italy) SAR302503 (phase 3
More informationCurrent Prognostication in Primary Myelofibrosis
Current Prognostication in Primary Myelofibrosis Francisco Cervantes Hematology Department, Hospital Clínic, Barcelona, Spain Florence, April 2011 Survival in PMF No. patients: 1,054 Median Srv (95% CI):
More informationDisclosures for Angela Fleischman
Disclosures for Angela Fleischman Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Sierra, Incyte None None None Incyte None Presentation includes
More informationNew WHO Classification of Myeloproliferative Neoplasms
New WHO Classification of Myeloproliferative Neoplasms Hans Michael Kvasnicka Senckenberg Institute of Pathology, University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Principles and rationale
More informationJAK inhibitors in Phmyeloproliferative
Disclosures for A Pardanani Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board TargeGen, Cytopia/YM BioSciences, PharmaMar None None None None None Presentation
More informationMolecular aberrations in MPN. and use in the clinic. Timothy Devos MD PhD
Molecular aberrations in MPN and use in the clinic Timothy Devos MD PhD MB&C2017 24-3-2017 Introduction 1951: William Dameshek MPD MPN = clonal, hematopoietic stem cell disorders, proliferation in BM of
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationMyeloproliferative Neoplasms
Myeloproliferative Neoplasms Judit Demeter CML chronic myeloid leukemia Semmelweis University, I st Department of Internal Medicine PV polycythaemia vera ET essential thrombocythaemia MF myelofibrosis
More informationPrognostic models in PV and ET
Prognostic models in PV and ET Francesco Passamonti Hematology, Varese, Italy Current risk stratification in PV and ET: statement from European LeukemiaNet consensus Age over 60 years Previuos thrombosis
More informationWhat is next: Emerging JAK2 inhibitor combination studies. Alessandro M. Vannucchi. Section of Hematology, University of Florence, Italy
ymposium JAK2 Inhibition in Myelofibrosis: What Can We Expect in the Clinic? 4 5 May 2012 Lisbon, Portugal What is next: Emerging JAK2 inhibitor combination studies Alessandro M. Vannucchi ection of Hematology,
More informationPolycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi
Polycythemia Vera and other Myeloproliferative Neoplasms A.Mousavi Chronic MPNs Multipotent hematopoietic progenitor cell is origin. Overproduction of one or more formed element of blood cells without
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationPreliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
Preliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis Tamara K. Moyo, Andrew Sochacki, Gregory D. Ayers, Michael T. Byrne, Stephen A.
More informationClinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera
Clinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera Alessandro M. Vannucchi, MD Laboratorio Congiunto MMPC Department of Experimental and Clinical Medicine University
More informationWinship Cancer Institute of Emory University New Determinants and Approaches for MPN
Winship Cancer Institute of Emory University New Determinants and Approaches for MPN Elliott F. Winton August 8, 2014 Sea Island, Georgia Outline: MPN Determinants, Approaches Diagnosis Prognosis Treatment
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Ruxolitinib (Jakavi) for Myelofibrosis January 14, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Ruxolitinib (Jakavi) for Myelofibrosis January 14, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationMYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).
MYELOPROLIFARATIVE NEOPLASMS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin). These are a group of chronic conditions characterised by clonal proliferation of marrow precursor cells. PRV, essential thrombocyathaemia,
More informationUnmet Medical Needs in Myelofibrosis
Unmet Medical Needs in Myelofibrosis October 17, 2018 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationTreatment free remission 2016
Treatment free remission 2016 Pr Ph Rousselot Université de Versailles Saint-Quentin-en-Yvelines Hôpital André Mignot, Hôpitaux de Versailles, France How many patients still on imatinib? Versailles cohort
More informationMayo Clinic, Scottsdale, AZ, USA; 14 MD Anderson Cancer Center, Houston, TX, USA.
RESULTS OF THE PERSIST-2 PHASE 3 STUDY OF PACRITINIB (PAC) VERSUS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB (RUX), IN PATIENTS WITH MYELOFIBROSIS (MF) AND PLATELET COUNTS 100,000/µL John Mascarenhas
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationBone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany
Bone marrow histopathology in Ph - CMPDs - the new WHO classification - Juergen Thiele Cologne, Germany Current issues in MPNs concerning morphology 1.Prodromal stages of disease 2.Impact of histopathology
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders Myeloproliferative Neoplasms
Clinical Guidelines for Leukaemia and other Myeloid Disorders Myeloproliferative Neoplasms Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 1
More informationASCO 2011: Leukemia. Disclosures
ASCO 2011: Leukemia E.J. Feldman M.D Weill-Cornell Medical College Disclosures Speaker does not report any affiliations 1 V617F JAK2 mutation in MPDs JAK STAT PATHWAY Signal transducers and activators
More informationTreatment of polycythemia vera with recombinant interferon alpha (rifnα)
Treatment of polycythemia vera with recombinant interferon alpha (rifnα) Richard T. Silver, MD Professor of Medicine Weill Cornell Medical College New York, New York Outline of Lecture What are interferons?
More informationHighlights in myeloproliferative neoplasms
CONGRESS HIGHLIGHTS 6 Highlights in myeloproliferative neoplasms T. Devos, MD PhD SUMMARY The presentations on myeloproliferative neoplasms at this year s ASH congress were inspiring and innovative. As
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationCML: Role of combination treatments, Interferon and immunotherapy in CML
CML: 2017 Role of combination treatments, Interferon and immunotherapy in CML Andreas Burchert Philipps Universität Marburg Universitätsklinikum Gießen und Marburg GmbH Key Developments that will Change
More informationOVERALL CLINICAL BENEFIT
noted that there are case reports of a rebound effect upon discontinuation of ruxolitinib (Tefferi 2012), although this was not observed in either the COMFORT I or COMFORT II studies. Therefore, perc considered
More informationThe Evolving Role of Transplantation for MPN
The Evolving Role of Transplantation for MPN (PMF, PV, ET) H.Joachim Deeg MD Fred Hutchinson Cancer Research Center, University of Washington, Seattle WA, SCCA jdeeg@fhcrc.org 10 th J. Niblack Conference
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationNew Therapies for MPNs
Pomalidomide and IMIDS in Myelofibrosis New Therapies for MPNs Fourth International Workshop on CML and MPN Natchez Louisiana Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Director
More informationWHO 2016/17 update on Myeloproliferative Neoplasms. Anna Ruskova Auckland City Hospital New Zealand
WHO 2016/17 update on Myeloproliferative Neoplasms Anna Ruskova Auckland City Hospital New Zealand BLOOD, 19 MAY 2016 x VOLUME 127, NUMBER 20 2 2016/17 Classification of Myeloproliferative Neoplasms Chronic
More informationDisclosures. I do not have anything to disclose. Shared Features of MPNs. Overview. Diagnosis and Molecular Monitoring in the
Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Target Therapy Era C. Cameron Yin, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Disclosures I do not have
More informationSponsor / Company: Sanofi Drug substance(s): SAR302503
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More informationMyeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Era of Target Therapy
Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Era of Target Therapy C. Cameron Yin, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Disclosures I do not
More informationMDS/MPN MPN MDS. Discolosures. Advances in the Diagnosis of Myeloproliferative Neoplasms. Myeloproliferative neoplasms
Discolosures Advances in the Diagnosis of Myeloproliferative Neoplasms Consulting income from Promedior, Inc. Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationTisch Cancer Institute, Icahn School of Medicine at Mount Sinai; MPN-RC (US), 2 H Lee Moffitt Cancer Center (US), 3
Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study
More informationPhiladelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 26 (Supplement 5): v85 v99, 2015 doi:10.1093/annonc/mdv203 Published online 4 August 2015 Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice
More informationDisclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.
RC1 Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations RC2 Disclosure: Nothing to disclose Henry Moon Lecture: UCSF Annual Conference Kathryn Foucar, MD kfoucar@salud.unm.edu May
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationMYELOPROLIFERATIVE NEOPLASMS
9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationCase Presentation. Attilio Orazi, MD
Case Presentation Attilio Orazi, MD Weill Cornell Medical College/ NYP Hospital Department of Pathology and Laboratory Medicine New York, NY United States History 60 year old man presented with anemia
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationASH 2013 Analyst & Investor Event
ASH 2013 Analyst & Investor Event December 9, 2013 John A. Scarlett, MD President & CEO Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking
More informationMyeloproliferative Neoplasms
Myeloproliferative Neoplasms (MPN and MDS/MPN) Attilio Orazi, MD, FRCPath Weill Cornell Medical College/ NY Presbyterian Hospital, New York, NY USA EAHP EDUCATIONAL SESSION: Updated WHO classification
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationWhat is New in Leukemia & MPN in 2011?
Leukemia Update What Did We Learn from ASCO 211? Jorge Cortes, MD Department of Leukemia MD Anderson Cancer Center Houston, Texas What is New in Leukemia & MPN in 211? Cool things happening in MPN The
More information